Background: Treatment of superficial venous reflux in addition to compression therapy accelerates venous leg ulcer healing and reduces ulcer recurrence. The aim of this study was to evaluate the costs and cost-effectiveness of early versus delayed endovenous treatment of patients with venous leg ulcers.
Introduction
Leg ulcers are a major burden to healthcare providers and represent a source of discomfort and social isolation to patients. In 70 per cent of cases, the underlying cause of leg ulceration is venous disease, sometimes evident as varicose veins but often undetectable by visual examination alone. One UK study 1 found a point prevalence of 1⋅5 cases of complex wounds per 1000 population, of which 28 per cent were leg ulcers. It should also be noted that, with an ageing and increasingly obese population, the incidence and prevalence of venous ulceration are both likely to increase. Treatment of venous leg ulcers has been estimated to cost £941 (€1061) million per annum in the UK 2 .
Venous leg ulcers are characterized by protracted healing. Some ulcers may never heal, and those that do are at high risk of recurrence 3 . The mainstay of therapy for venous ulceration is compression therapy using bandages or stockings 3 . Current guidelines 4 recommend treatment of superficial venous reflux using endovenous ablation techniques (ultrasound-guided foam sclerotherapy (UGFS), endovenous laser or radiofrequency ablation), but many practitioners delay intervention until the ulcer has healed. More recently, the EVRA (Early Venous Reflux Ablation) trial 5 found that early endovenous ablation significantly reduced time to ulcer healing. This study presents an analysis of the cost-effectiveness of early versus delayed endovenous treatment, based on the EVRA trial data to 1 year. The protocol is available at http://www.imperial .ac.uk/media/imperial-college/medicine/surgery-cancer/ clinical-trials/EVRA-Protocol-06.04.2017.pdf.
Methods
This study was a within-trial cost-utility analysis comparing early versus deferred endovenous ablation for truncal superficial venous reflux in patients with venous ulceration, within a 1-year time horizon. The primary difference between the two strategies was the timing of endovenous ablation: patients in the early intervention arm were treated within 2 weeks of randomization, whereas those randomized to the deferred intervention arm underwent endovenous ablation once the ulcer had healed, or after 6 months. All patients were treated with compression therapy in accordance with local standard practice.
Patients in the EVRA trial were aged at least 18 years, presented with a venous leg ulcer of between 6 weeks' and 6 months' duration, ankle : brachial pressure index 0⋅8 or above, able to tolerate compression therapy, and had superficial venous reflux requiring endovenous ablation. Patients were recruited from 20 vascular centres in the UK, and endovenous interventions were performed in outpatient clinic, operating room or treatment room settings (as per local practice). Most leg ulcer management takes place in a community care setting (community clinics or patient's home) or in primary care clinics.
Outcome assessment
The cost analyses were performed from the perspective of the UK National Health Service and Personal Social Services in accordance with UK methods guidance 6 . The price year was 2015-2016, and currency conversion was calculated at 2016 purchasing power parity 7 . No discounting was applied as the follow-up was 1 year. The study was reported according to guidelines for economic evaluation 8 .
The primary health outcome in the cost-effectiveness analysis was quality-adjusted life-years (QALYs) at 1 year. Participants in the EVRA study were asked to complete the EQ-5D-5L™ (EuroQol Group, Rotterdam, the Netherlands) questionnaire at baseline, 6 weeks, 6 months and 1 year after randomization. EQ-5D™ is an instrument to measure generic health-related quality of life and has been validated in patients with leg ulcers, the EVRA population 9 . To convert patient responses into a health utility scale (where 1 represents perfect health and 0 a state equivalent to death), the base-case economic analysis used the crosswalk tariff 10 , as recommended by the UK National Institute for Health and Care Excellence (NICE) in August 2017. This algorithm maps the EQ-5D™ five-level responses to three-level responses, and then values those health states using the original EQ-5D™ three-level tariff developed by Dolan 11 . As a sensitivity analysis, an alternative health utility tariff developed by Devlin and colleagues 12 for the EQ-5D-5L™ was used. Quality-adjusted life-years (QALYs) were estimated for each participant to 1 year as the area under the curve of EQ-5D-5L™ index values.
Resource use items were recorded for each participant at monthly follow-up telephone calls. The total cost per patient included the following resource items for vein or ulcer-related reasons: trial endovenous ablation procedures, dressings and bandaging consumables for wound healing, compression therapy to prevent recurrence after wound healing, visits to or from a district nurse, visits to or from a general practitioner, visits to a primary care practice nurse, inpatient and day-case hospital admissions, outpatient visits, use of antiplatelet and anticoagulant medicines, physiotherapy and occupational therapy, auxiliary nursing (home care) and personal care (home help).
To obtain a precise estimate of the effect of the intervention on healthcare use, and avoid statistical noise, the study aimed to include only resource use related to the ulcer. Researchers recorded the reason for the use of each item of healthcare as free text. Ulcer-related activity was considered to include: ulcer care, skin care, leg care, venous procedures, angiography, infection, rehabilitation, deep vein thrombosis and related keywords. Non-ulcer-related healthcare, as well as out-of-pocket expenses and time lost from usual activities, were tabulated but not included in total cost per patient. Costs were estimated by multiplying resource use by unit costs obtained from published literature 13 , national unit cost databases for the UK 14 -18 , and manufacturers' list prices for catheters and other disposable items (Table S1 , supporting information). Currency conversions from GBP (£) to euros (€) were calculated to 
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Values in parentheses are percentages unless indicated otherwise; *values are mean(s.d. the rate applicable at the time of conversion (£1 = €1⋅1273; exchange rate 20 September 2018).
Handling of missing data
There was a small amount of missing data in the trial owing to patient withdrawal and other reasons. Costs and EQ-5D-5L™ index were set to zero after the date of death. The base-case cost-effectiveness analysis used complete cases in an intention-to-treat analysis. A participant was considered a complete case if they completed all the EQ-5D™ questions at baseline, 6 weeks, 6 months and 1 year, and did not withdraw from the study before 12 months.
As a sensitivity analysis, multiple imputation using chained equations was employed to impute the remaining missing data by regression under the assumption of 'missingness at random' 19 . Missing costs in each treatment group were considered predictable from observed data, plus or minus a random error. For those lost to follow-up, costs for each participant were imputed at each month after the time of withdrawal, and the EQ-5D-5L™ index was imputed at 6 weeks, 6 months and 1 year if these data were missing. Ten imputed data sets were created and analysed using Rubin's rules (this was sufficient to give stable results allowing for Monte Carlo error) 19 . 
Handling of protocol deviations
In the clinical study, protocol deviations were seen in 117 patients (59 and 58 in the early and deferred groups respectively), the majority of which were late or missed follow-up appointments (40 of 59 patients in the early intervention group and 34 of 58 in the deferred intervention group) 5 . A sensitivity analysis was carried out excluding these patients.
Cost-effectiveness analysis
The difference in mean total cost and mean total QALY per participant between the treatment groups was estimated using regression methods, including baseline EQ-5D-5L™ in the QALY regression Monte Carlo resamples 20 .
The incremental cost-effectiveness ratio (ICER) was calculated. An intervention may be considered cost-effective when its ICER is less than the threshold set by health policy decision-makers 21 . In the UK, the cost-effectiveness threshold is in the range £20 000-30 000 (€22 546-33 819) per QALY 6 .
The probability that early ablation was more cost-effective than deferred ablation was estimated at different cost-effectiveness thresholds. The base-case analysis used bootstrapping, with 1000 Monte Carlo resamples with replacement. The bootstrap was used only for the analysis of complete cases, as bootstrap combined with multiple imputation can be very complex 22 . As an alternative method in sensitivity analyses, standard errors and correlation between total costs and QALYs were estimated assuming bivariable normality (Appendix S1, supporting information).
Sensitivity analyses
Five models were estimated: model 1, the base case -complete cases with bootstrap standard errors and crosswalk EQ-5D-5L™ tariff; model 2, complete case with bivariable normal standard errors and crosswalk EQ-5D-5L™ tariff; model 3, multiple imputation with bivariable normal standard errors and crosswalk EQ-5D-5L™ tariff; model 4, complete case with bootstrap standard errors and EQ-5D-5L™ tariff estimated according to Devlin et al. 12 ; model 5, per-protocol analysis (this was the same as model 1, but excluded patients with a protocol deviation).
Results
Baseline characteristics for the study groups, described in full elsewhere 5 , were evenly matched across the arms of the EVRA trial ( Table 1) .
Resource use and total cost analysis
The total mean cost per patient over 1 year, excluding patients who did not complete follow-up to 12 months is shown in Table S2 (supporting information). Participants who died during the year were included in these data, with costs set to zero after the date of death. For the purposes of this analysis, 419 patients completed 12 months of the study or died, 211 in the deferred ablation group (226 randomized, less 15 withdrawals or lost to follow-up) versus 208 in the early group (224 randomized, less 16 withdrawals or lost to follow-up). The total mean(s.d.) cost per patient over 1 year was similar in the two study groups: £2514(2770) (€2834(3123)) for 208 patients randomized to early ablation versus £2516(3242) (€2836(3655)) for 211 patients in the deferred group (Fig. 1) .
The early ablation group incurred a greater initial cost due to the allocated endovenous ablation procedure. Although the study protocol recommended that participants in the deferred group should have an ablation procedure once the ulcer had healed, many did not receive this treatment. At 1 year, 55 of the 226 patients in the deferred arm had received no intervention, compared with seven of 224 in the early arm (Table S2 , supporting information). Of the 55 with no intervention in the deferred arm, 35 subjects completed the study, of whom 26 had a healed ulcer after 1 year. Reasons for not performing ablation procedures in participants randomized to deferred ablation were unclear, but both participant and clinician preferences are likely to have played a role. The greater initial costs in the early ablation group were compensated by lower costs of district nurse home visits due to quicker wound healing (Table S2 , supporting information). Other resource use was similar in the two groups. Table 2 shows the results of the cost and QALY regressions for the cost-effectiveness analyses. In the complete-case analysis (model 1 or base case), 106 of 450 patients (23⋅6 per cent) had incomplete EQ-5D™ or cost data over the year, and thus 344 (76⋅4 per cent) were included in this analysis. The proportion of missing data was similar in the early (22⋅8 per cent) and deferred (24⋅3 per cent) intervention arms. Greater costs and QALYs were recorded for patients in the early intervention group, with a mean(s.e.m.) difference in cost per patient of £163(318) (€184(358)), a difference in QALYs at 1 year of 0⋅041(0⋅017). The ICER was £3976 (€4482)/QALY. There was an 89 per cent probability that early endovenous intervention is cost-effective at a threshold of £20 000 (€22 546)/QALY (Fig. 2) . When bivariable normality was assumed to estimate standard errors, the results were similar (model 2). There was a significant negative correlation between costs and QALYs, indicating that participants with a worse quality of life were also those who tended to incur greater healthcare costs (correlation -0⋅294, P < 0⋅001).
Cost-effectiveness analysis
In model 3, missing data were imputed. All 450 randomized patients were included in this model. The mean(s.e.m.) difference in total cost was −£72(290) (−€81(327)) (early intervention was cost-saving) and the mean difference in QALYs over 1 year was 0⋅058(0⋅018) (greater in the early intervention group), with more than 99 per cent probability of being cost-effective at a threshold of £20 000 (€22 546)/QALY. The use of alternative tariff values for the EQ-5D-5L™ (model 4) resulted in a slightly smaller difference in QALYs between the treatment groups than for the base case, but the ICER was similar.
The per-protocol analysis was carried out using the same approach as model 1, but excluding patients with protocol deviations. Protocol deviations were seen in 117 patients (59 and 58 in early and deferred groups respectively), of whom 71 had complete data. This left 273 patients for analysis (344 with complete data at 12 months, less 71 protocol deviations). The ICER was £8679 (€9784)/QALY (model 5).
Discussion
This study has demonstrated that early endovenous intervention for superficial venous reflux is highly likely to be a cost-effective treatment for patients with a venous leg ulcer. The complete-case analysis showed little difference in total mean cost per patient over 1 year between the early and deferred ablation strategies (mean(s.e.m.) difference £163(318) (€184(358); P = 0⋅607). The greater initial mean cost of the early intervention strategy was mostly offset by the reduced cost of treating unhealed leg ulcers. There was, however, a substantial and statistically significant gain in QALYs over 1 year, with a mean difference of 0⋅041(0⋅017) in favour of early intervention (P = 0⋅017). The ICER for early intervention at 1 year is therefore £3976 (€4482)/QALY.
From the complete-case analysis, the probability of cost-effectiveness was 89 per cent using UK thresholds. Therefore, there is little chance that delayed ablation would offer greater net benefit at conventional thresholds of willingness-to-pay. Sensitivity analyses using alternative statistical models gave qualitatively similar results.
This economic analysis compared early versus delayed endovenous ablation for venous leg ulcers. Tricco and colleagues 23 reviewed studies that evaluated the costs and benefits of alternative medical therapeutic strategies. It was notable that the difference in QALYs between the strategies reported by these studies was generally small. For example, the largest QALY gain observed in any previous study was in VenUS I (difference of 0⋅02 QALYs for four-layer bandages versus short stretch bandages) 24 . The difference in QALYs between early and delayed ablation found in the present study was much larger: 0⋅041 over 1 year. This study did not consider whether cost-effectiveness might vary across subgroups. The EVRA trial 5 assessed the clinical benefit across several predefined subgroups and detected some interesting trends for potentially greater benefits for early intervention, such as in patients with longer ulcer duration. However, the clinical study was not powered to detect differences across subgroups, and furthermore patients with ulcer duration of more than 6 months were excluded. Thus, further studies are required to confirm these findings and assess whether there may be greater cost-effectiveness in these populations, or with specific endovenous interventions such as UGFS.
The benefits of early endovenous ablation in the present study arose because of faster ulcer healing in the first 12 months after randomization. The long-term benefits and costs will also depend on whether the treatments can reduce ulcer recurrence rates. Evidence from other randomized trials suggests that surgical intervention for superficial reflux reduces recurrence, compared with compression therapy alone 25 . If early endovenous ablation can impact on both healing and recurrence, it could be even more cost-effective over the patient's lifetime 26 . In the EVRA study, there were insufficient recurrences over 1 year to permit meaningful comparison. Evaluation of ulcer recurrence in the EVRA population is ongoing.
This study showed that early endovenous ablation had a significant and substantial impact on a patient's quality of life, with no material increase in the burden of cost on payers. Hence this strategy is very likely to be cost-effective. The resources needed for implementation of an early intervention strategy will depend on the individual setting 3 , but any effective wound management strategy would require close multidisciplinary teamwork between primary care and specialist vascular centres to conduct prompt assessment of patients with a venous leg ulcer, referral and treatment of superficial venous reflux.
